Emerging Growth Conference 88 December 11, 2025 9:05 AM ESTCompany ParticipantsJean-Marie Clouet - Vice President ...
Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including hemogl ...
IBI3003 is a novel trispecific antibody targeting GPRC5D, BCMA and CD3 simultaneously. Its dual-targeting design against BCMA and GPRC5 aims to overcome single antigen escape in multiple myeloma (MM).
Detailed price information for Assembly Biosciences (ASMB-Q) from The Globe and Mail including charting and trades.
In recent days, Rocket Companies participated in high-profile presentations at both the Stephens Annual Investment Conference and Deutsche Bank's Financial Services IRO Summit, highlighting its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results